Navigation Links
U.S. Commerce Secretary Gutierrez Cuts Ribbon on MaxWell Biocorporation's New Pharmaceutical Development Center and Quality Control Laboratory in Ukraine

- First U.S. Commerce Secretary to visit independent Ukraine also visits

MaxWell's newly-built Boryspil facility -

WASHINGTON, June 24 /PRNewswire/ -- On June 4, 2008, U.S. Commerce Secretary Carlos Gutierrez became the first U.S. cabinet official to visit MaxWell Biocorporation's 150,000-square-foot pharmaceutical production facility in Boryspil, Ukraine.

(Logo: )

Gutierrez joined the founder, President and CEO of MaxWell Biocorporation Dr. Ken Alibek to officially open MaxWell's new pharmaceutical development center and quality control laboratory, co-located with the larger pharmaceutical production facility that opened officially on March 26, 2008.

Gutierrez and Alibek were joined at the ribbon-cutting ceremony by U.S. Ambassador to Ukraine William Taylor, President of the Academy of Medical Sciences of Ukraine Olexander F. Vozianov, and representatives of leading pharmaceutical companies in Ukraine.

Gutierrez visited MaxWell Biocorporation's Boryspil facility during his official trip to Ukraine on June 4-5. The U.S. Commerce Secretary also addressed the American Chamber of Commerce in Kyiv, held a roundtable discussion with U.S. business leaders, and met with Ukraine's President Yushchenko, Prime Minister Tymoshenko, and other senior Ukrainian officials to promote greater bilateral trade and investment.

According to the U.S. Department of Commerce, bilateral trade between the United States and Ukraine exceeded $2.5 billion in 2007, with U.S. exports growing by more than 77 percent. Ukraine's pharmaceutical market alone grew an estimated 22% in 2007, with 12% growth predicted for 2008.

Earlier this year, the United States and Ukraine concluded a Trade and Investment Cooperation Agreement, which establishes a framework for a deeper dialogue on trade and investment.

Photos of the event may be accessed on the MaxWell corporate website ( and on the U.S. Commerce Department home page ( ).

About MaxWell

MaxWell Biocorporation is a U.S.-based, privately-held international medical and pharmaceutical company with wholly owned subsidiaries and affiliates in the United States and Ukraine dedicated to increasing life expectancy and improving the quality of life of people in Ukraine and other underserved emerging healthcare markets in the former Soviet Union. MaxWell targets oncological, cardiological, chronic infectious and autoimmune disorders and diseases through the development, production, and introduction into clinical practice of sophisticated, high quality, and affordable off-patent generic biopharmaceutical and chemopharmaceutical medicines and the latest diagnostic and therapeutic methods. MaxWell = "Maximum Wellness."

"We Help You Live Longer"


Alex Meerovich


SOURCE MaxWell Biocorporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. U.S. Commerce Secretary Gutierrez to Address AdvaMed 2007
2. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
3. HHS Secretary Leavitt Announces Members of the National Biodefense Science Board
4. Carbon nanoribbons could make smaller, speedier computer chips
5. CTDC Holds a Ribbon Cutting Ceremony to Showcase First SnO2 Production Line
6. Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taros Irish Subsidiary
7. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
8. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
9. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
10. In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict
11. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology:
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):